A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL) [CheckMate 647]
There is no standard therapy for primary central nervous system (CNS) lymphoma or primary testicular lymphoma that has come back despite prior therapy. In this study, researchers are evaluating the safety and effectiveness of using the immunotherapy drug nivolumab in these patients. Nivolumab is given intravenously (by vein).
Nivolumab boosts the body's immune system by targeting a protein on white blood cells called PD-1. PD-1 normally maintains the balance of the immune system by shutting it down at the right time. Some cancers take advantage of this mechanism by expressing PD-L1, enabling them to escape attack by the body's white blood cells. Nivolumab blocks PD-1, enhancing the body's ability to detect and destroy cancer cells. It is approved for treating several types of cancer; its use in this study is considered investigational.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have primary CNS lymphoma or primary testicular lymphoma that has continued to grow or came back despite previous treatment.
- Patients may not have previously received nivolumab or immunotherapies that work in similar ways.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Connie Batlevi at 212-639-8081.